ClinicalTrials.gg
Not yet recruitingNCT07146009Updated Aug 28, 2025

Targeted Nerve Surgery for the Prevention of Post-Mastectomy Pain Syndrome: A Randomized Trial

An interventional study of Nerve Surgery and Standard of Care (Investigator Choice) in Breast Cancer, sponsored by Advanced Reconstructive Surgery Alliance. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-28.

Sponsored by Advanced Reconstructive Surgery Alliance · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Post-Mastectomy Pain Syndrome (PMPS) is a chronic pain condition often caused by neuroma formation and nerve injury following breast cancer surgery. Standard breast reconstruction protocols typically do not address damaged intercostal nerves, leaving patients at risk for persistent nerve-related pain.

Prophylactic nerve surgery techniques, such as Targeted Muscle Reinnervation (TMR) and Regenerative Peripheral Nerve Interfaces (RPNI), offer innovative approaches to prevent neuroma formation by managing damaged nerves during surgery. This study will evaluate whether incorporating prophylactic nerve surgery during second-stage implant exchange after tissue expander based breast reconstruction can reduce the incidence of PMPS compared to standard medical therapies.

02

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Post-mastectomy pain syndrome (PMPS)
  • Breast reconstruction
  • Regenerative Peripheral Nerve Interfaces
  • Targeted Muscle Reinnervation
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Advanced Reconstructive Surgery Alliance is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥18 years old) undergoing second-stage implant exchange as part of tissue expander based breast reconstruction.
  • Patients with no prior diagnosis of PMPS.

Exclusion criteria

Exclusion Criteria:

  • Prior nerve surgery in the chest region or chronic pain conditions unrelated to mastectomy.
  • Recent chest radiation (\<6 months), severe scarring, or active infection.
  • Uncontrolled diabetes, high-dose , or therapy.
  • Psychiatric or cognitive impairments.
  • Pregnancy, or active lactation.
  • Autologous tissue based breast reconstruction.
  • Participation in another study within 6 months or inability to comply with follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Standard of care

    Patients receiving standard medical therapies for PMPS prevention (e.g., pharmacologic pain management, physical therapy).

    Other: Standard of Care (Investigator Choice)

  • Experimental
    Nerve Surgery

    Patients undergoing prophylactic nerve surgery (RPNI) during second-stage implant exchange after tissue expander based breast reconstruction.

    Procedure: Nerve Surgery

Interventions

  • ProcedureNerve Surgery

    Patients undergoing prophylactic nerve surgery (RPNI) during second-stage implant exchange after tissue expander based breast reconstruction.

  • OtherStandard of Care (Investigator Choice)

    Patients receiving standard medical therapies for PMPS prevention (e.g., pharmacologic pain management, physical therapy).

06

What researchers measure

Primary outcomes

  1. Incidence of Post-Mastectomy Pain Syndrome

    Incidence of PMPS, defined as persistent pain beyond 6 months postoperatively.

    Time frame: Pre-operative visit (baseline) to 12 months.

Secondary outcomes

  1. Breast Cancer Pain Questionnaire

    Pain severity scores at 3, 6, and 12 months.

    Time frame: Pre-operative visit (baseline) to 12 months.

  2. Adverse event rates

    Complication and adverse event rates.

    Time frame: Pre-operative visit (baseline) to 12 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Oct 2027, 24 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 24 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2025
First posted
Aug 28, 2025
StartEst.
Oct 2025
Primary completionEst.
Oct 2027
CompletionEst.
Feb 25, 2028
Last update
Aug 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07146009
Lead sponsor
Advanced Reconstructive Surgery Alliance
Responsible party
Kari Colen (Medical Doctor, Advanced Reconstructive Surgery Alliance) — Principal investigator
First posted
Aug 28, 2025
Start date
Oct 2025 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Aug 28, 2025

Study contacts

Grace Wells, BS
Contact
gwells@sycamoremm.com
732-741-0970 ext. 1889
Kari Colen, MD
principal investigator · Advanced Reconstructive Surgery Alliance

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion